Biomerica (NASDAQ: BMRA) — Perfil da empresa, notícias e dados financeiros
Biomerica develops diagnostic and therapeutic products focused on gastrointestinal diseases and diabetes management, improving patient care.
Biomerica
Biomerica (NASDAQ:BMRA) is a global biomedical technology company focusing on the development, manufacturing, and marketing of diagnostic and therapeutic products. Its portfolio primarily targets gastrointestinal diseases, food intolerances, and diabetes management. Biomerica aims to innovate in the health sector by delivering cost-effective solutions that can improve patient outcomes and access to care. The company's projects range from early detection tools for diseases to sophisticated monitoring devices, aligning with its objectives to enhance diagnostic accuracy and support personalized treatment strategies. Through strategic partnerships and continuous research, Biomerica strives to expand its global footprint and bring groundbreaking products to markets worldwide, addressing the unmet needs in health management and patient care.
Resumo
Operações
Produtos e/ou serviços de Biomerica
- EZ Detect, a simple, non-invasive test to detect fecal occult blood, indicating gastrointestinal disorders like colorectal cancer.
- HpSA, an easy, non-invasive test designed to detect Helicobacter pylori bacteria, a major cause of peptic ulcers.
- InFoods IBS, an innovative diagnostic-guided therapy designed to identify specific foods that may aggravate irritable bowel syndrome (IBS) symptoms.
- Colorectal cancer screening test kit, offering easy and accurate at-home screening solutions to detect early signs of colorectal cancer.
equipe executiva do Biomerica
- Zackary S. IraniCEO & Director
- Allen C. BarbieriExecutive Vice-Chairman of the Board & Corporate Secretary
- Xiaoxuan QuPrincipal Financial Officer & Principal Accounting Officer
- Lucy LiuDirector of Manufacturing & Technical Operations
- Scott MadelChief Commercial Officer
Principais indicadores financeiros
Resultados divulgados pela Biomerica, em USD.
- Cap. de mercado
- 8 mi
- Receita (TTM)
- 4,3 mi
- P/L
- —
- LPA (diluído, TTM)
- -1.6
- Dividend yield
- —
- Margem de lucro
- -115.5%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 4,5 mi | -5,3 mi | -3,8 mi | |
| 5,3 mi | -5,1 mi | -5 mi | |
| 5,4 mi | -6,4 mi | -6 mi | |
| 5,3 mi | -7,2 mi | -7,1 mi |